When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
Chonnam Medical Journal · 2023 · 59 (3) · 180
DOI: 10.4068/cmj.2023.59.3.180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chonnam Medical Journal, 2023. Verfasst von Hong-Joon Shin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: COPD
Abstract (Originalsprache)
Long-acting β2-agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual therapy has been found to be more effective than LAMA monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). However, among patients with group B or D COPD, the characteristics of patients for whom LABA/LAMA dual therapy is superior to LAMA monotherapy in minimizing acute exacerbations remain unknown. With data from a prospective COPD cohort, subgroup analyses were conducted to determine whether LABA/LAMA dual therapy was superior to LAMA monotherapy in reducing the rate of acute exacerbations in group B and D COPD patients. Group B and D COPD patients taking LAMA or LABA/LAMA were enrolled according to the 2022 Global initiative for Chronic Obstructive Pulmonary Disease guidelines. A total of 737 patients were included in this study: 600 with group B COPD and 137 with group D COPD. Compared with patients taking LAMA monotherapy, those taking LABA/LAMA had a significantly lower incidence of acute exacerbations over 1 year. In the subgroup of patients ≥70 years old, there was a significantly lower risk of severe COPD exacerbations among group B patients taking LABA/LAMA than among those taking LAMA monotherapy (odds ratio [OR], 0.258; 95% confidence interval [CI], 0.095-0.703). In contrast, in the subgroup of group D patients with COPD Assessment Test scores ≥25, compared with LAMA monotherapy, LABA/LAMA treatment was associated with lower risk of severe COPD exacerbations (OR, 0.115; 95% CI, 0.018-0.749). The combination of LABA and LAMA was found to be superior to LAMA monotherapy, especially for treating older adults with group B COPD, as well as for group D patients with severe symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary Medicine, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
- Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Zitieren
APA
Shin, H. J., Kim, Y. I., Kim, Y., Lee, C. Y., Ra, S. W., Moon, J. Y., Jung, K. S., Yoo, K. H., Shin, K. C., Lim, S. C., & KOCOSS Cohort Study Group (2023). When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?. Chonnam Medical Journal, 59(3), 180. https://doi.org/10.4068/cmj.2023.59.3.180
Vancouver
Shin HJ, Kim YI, Kim Y, Lee CY, Ra SW, Moon JY, et al. When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?. Chonnam Medical Journal. 2023;59(3):180. doi:10.4068/cmj.2023.59.3.180
BibTeX
@article{Shin2023,
author = {Shin, Hong-Joon and Kim, Yu-Il and Kim, Youlim and Lee, Chang Youl and Ra, Seung Won and Moon, Ji-Yong and Jung, Ki-Suck and Yoo, Kwang Ha and Shin, Kyeong-Cheol and Lim, Sung-Chul and KOCOSS Cohort Study Group, KOCOSS Cohort Study Group},
title = {When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?},
journal = {Chonnam Medical Journal},
year = {2023},
volume = {59},
number = {3},
pages = {180},
doi = {10.4068/cmj.2023.59.3.180}
}
EUVIMED